• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Connective Tissue Disease Companies

    ID: MRFR/Pharma/3542-HCR
    85 Pages
    Rahul Gotadki
    October 2025

    Connective tissue diseases (CTDs) encompass a group of disorders that affect the connective tissues, including the skin, joints, blood vessels, and internal organs. These diseases can have autoimmune or inflammatory components. While there may not be companies exclusively focused on connective tissue diseases, pharmaceutical companies, biotechnology firms, and research institutions may be actively involved in developing treatments and therapies for various CTDs. 

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Global Connective Tissue Disease Market Research Report- forecast till 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Connective Tissue Disease Market

    Connective Tissue Disease Key Companies

     

    Latest Connective Tissue Disease Companies Update


    November 2023: Immunic Therapeutics Inc. acquired Celgene Corporation's late-stage development pipeline for Sjogren's syndrome, strengthening their focus on rare autoimmune diseases.July 2023: AbbVie entered into a collaboration with the Lupus Foundation of America to advance research and development efforts for Lupus.December 2023: Viela Bio Inc. secured $150 million in Series C funding to advance its pipeline of therapies for autoimmune and inflammatory diseases, including Scleroderma.September 2023: Biogen Inc. received $75 million in funding from the National Institutes of Health to develop a novel gene therapy for Myositis.January 2024: AstraZeneca received FDA approval for Uplizumab (Enbryta) for the treatment of moderate-to-severe Giant Cell Arteritis.October 2023: Roche launched Enspryng (satralizumab) in Europe for the treatment of neuromyelitis optica spectrum disorder.November 2023: The European League Against Rheumatism launched a new initiative to improve access to early diagnosis and treatment for patients with connective tissue diseases in low- and middle-income countries.

     

    List of Connective Tissue Disease Key Companies in the Market



    • Abbott Laboratories

    • Bayer AG

    • Hoffmann-La Roche Ltd

    • Pfizer

    • AutoImmune Inc.

    • Johnson & Johnson

    • Amgen Inc.

    • AstraZeneca

    • Eli Lilly and Company

    • Biogen

    • LUPIN